Business Wire

Eaton’s Vehicle Group Facilities Aim to Minimize Environmental Impact With New Technologies and Systems

15.10.2020 16:00:00 EEST | Business Wire | Press release

Share

Power management company Eaton today announced its Vehicle Group is installing a variety of sustainable technologies, including energy efficient lighting systems, water conservation equipment and energy-generating solar panels, at its global manufacturing facilities to reduce the company’s environmental footprint.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005246/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s Vehicle Group site in Jining, China, installed a solar roof to generate electricity for the facility. (Photo: Business Wire)

Reducing water consumption and pollutants

To reduce water consumption and mitigate pollutants, Eaton’s Vehicle Group is installing wastewater systems featuring ultrafiltration and reverse osmosis technologies for the treatment of industrial process water at several of its facilities. The systems are designed to treat and reuse water for industrial purposes.

In addition, some facilities are managing their stormwater by increasing the permeability of their property, decreasing runoff rates to reduce erosion, and adding native plantings that don’t require watering.

Employees at Vehicle Group’s Valinhos, Brazil, facility initiated an innovative water conservation system that treats water used at the plant with physicochemical and biological processes. The treated water is then reused in restrooms ​and for cleaning. In the first month of operation the system saved 40 cubic meters of water and is projected to increase to 129 cubic meters of water savings per month as the process is refined.

Multiple Vehicle Group sites also have made progress in diverting grinding swarf waste from landfills. Swarf, a byproduct generated during metal-cutting processes when fluids such as oils, coolants and water are mixed with fine particles of metal and filtration media, is one of the most difficult waste streams to recycle. Through vendor partnerships, the Vehicle Group deployed a mobile centrifuge process that separates the materials, making it possible to reuse the fluid during manufacturing processes and recycle the metal particles.

Leveraging innovative technologies to reduce energy consumption

New lighting systems composed entirely of light-emitting diodes (LEDs), which utilize 70 percent less energy than traditional lighting technologies, are being added at Eaton’s Vehicle Group facilities. The LEDs are activated by motion sensors that detect when someone enters or exits an area and a wireless control system that manages every lighting fixture and tracks the status of each. The Vehicle Group’s Tczew, Poland, facility recently installed such a system and has already realized a large reduction in energy consumption resulting in savings of hundreds of dollars in monthly costs.

Many of the electrical systems within a facility are sourced from Eaton’s Electrical Sector, a global leader in power distribution, power quality, industrial automation and power control product and service solutions.

In addition to leveraging LEDs, some Vehicle Group sites are taking steps to produce their own power by installing massive solar panels on the roof. A 10,000-square-meter solar panel array was recently installed on the rooftop of the Vehicle Group’s Wuxi, China, facility, and it’s expected to generate 769 MWh of electrical power annually. Electricity generated will be used for manufacturing at the plant, reducing greenhouse gases by about 588 tons per year. Additionally, solar roofs were installed in the Nashik and Ranjangaon, India, plants, reducing more than a 1,000 tons of carbon dioxide emissions annually.

Constructed from the ground up with an environmental focus

The manufacturing facility in Aguascalientes, Mexico, was constructed with a number of new environmentally focused features, including motorized windows for natural ventilation, reflective roofs for low solar gain and a daylight harvesting system that uses natural light to minimize energy consumption.

The site features a lighting system composed entirely of LEDs, a cooling system with motorized windows for natural ventilation and a reflective roof to reduce heat detention, while dryers and a mist eliminator ensure quality air flows through the plant.

Driving the movement toward a circular economy

Eaton is joining the global movement to mitigate climate change, which includes science-based targets for cutting carbon emissions from the company’s operations by at least 50 percent by 2030, positioning Eaton to achieve carbon neutrality.

Eaton’s eMobility business is contributing to a carbon-free future by installing vehicle charging ports for electrified vehicles at all its global sites, which encourages employees to choose zero-emission cars for their workplace commute.

In an effort to reduce waste, Eaton also is committed to achieving zero waste-to-landfill (ZWTL) status at 100 percent of its manufacturing facilities by 2030, and the Vehicle Group is doing its part to contribute to this important effort. Eaton’s Vehicle Group continues to implement ZWTL initiatives at its sites around the world. In 2020, its Hastings, Nebraska, facility was added to its list of manufacturing sites that are zero waste-to-landfill certified, bringing the global Vehicle Group sites that are ZWTL compliant to 74 percent.

“We are extremely proud of how we’ve come together to upgrade our manufacturing facilities in a way that improves energy efficiency, minimizes the impact on the environment, and brings us closer to a carbon-free future,” said João Faria, president, Eaton’s Vehicle Group. “Our commitment to sustainability is part of our core mission to improve the quality of life and the environment for those who count on us today and in the decades to come.”

Read more about Eaton’s commitment to sustainability in its latest Sustainability Report.

Learn more about how Eaton is helping its customers conserve resources and reduce their carbon footprint.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2019 revenues were $21.4 billion, and we sell products to customers in more than 175 countries. We have approximately 92,000 employees. For more information, visit www.eaton.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye